Art

J-GLOBAL ID：201902221180028060   Reference number：19A2854410

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

頭頚部の再発性または転移性扁平上皮癌に対する化学療法と化学療法による化学療法とセツキシマブの単独または化学療法の比較:無作為化,非盲検,第3相試験【JST・京大機械翻訳】

Author (26)： Burtness Barbara (Yale School of Medicine and Yale Cancer Center, New Haven, CT, USA) ,  Harrington Kevin J (The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust National Institute of Health Research Biomedical Research Centre, London, UK) ,  Greil Richard (Paracelsus Medical University, Salzburg Cancer Research Institute, Salzburg, Austria) ,  Greil Richard (Cancer Cluster Salzburg, Salzburg, Austria) ,  Soulieres Denis (Centre Hospitalier de l’Universite de Montreal, Montreal, QC, Canada) ,  Tahara Makoto (National Cancer Center Hospital East, Kashiwa, Japan) ,  de Castro Gilberto (Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Brazil) ,  Psyrri Amanda (National Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece) ,  Baste Neus (Vall d’Hebron University Hospital, Barcelona, Spain) ,  Neupane Prakash (University of Kansas Medical Center, Kansas City, KS, USA) ,  Bratland .ANGS.se (Oslo University Hospital, Oslo, Norway) ,  Fuereder Thorsten (Medical University of Vienna, Vienna, Austria) ,  Hughes Brett G M (Royal Brisbane and Women’s Hospital and University of Queensland, Brisbane, QLD, Australia) ,  Mesia Ricard (Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain) ,  Ngamphaiboon Nuttapong (Ramathibodi Hospital, Mahidol University, Bangkok, Thailand) ,  Rordorf Tamara (University Hospital, Zurich, Switzerland) ,  Wan Ishak Wan Zamaniah (University Malaya, Kuala Lumpur, Malaysia) ,  Hong Ruey-Long (National Taiwan University Hospital, Taipei, Taiwan) ,  Gonzalez Mendoza Rene (Unidad de Investigacion en Salud, Chihuahua, Mexico) ,  Roy Ananya (Merck & Co, Kenilworth, NJ, USA) ,  Zhang Yayan (Merck & Co, Kenilworth, NJ, USA) ,  Gumuscu Burak (Merck & Co, Kenilworth, NJ, USA) ,  Cheng Jonathan D (Merck & Co, Kenilworth, NJ, USA) ,  Jin Fan (Merck & Co, Kenilworth, NJ, USA) ,  Rischin Danny (Peter MacCallum Cancer Centre, Melbourne, VIC, Austrialia) ,  Rischin Danny (University of Melbourne, Melbourne, VIC, Australia)
Material： Lancet
Volume： 394  Issue： 10212  Page： 1915-1928  Publication year： 2019 
JST Material Number： B0673A  ISSN： 0140-6736  CODEN： LANCA  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： Pembrolizumab is active in hea...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A2854410&from=J-GLOBAL&jstjournalNo=B0673A") }}

Thesaurus term： *drug therapy ,  platinum ,  effectiveness ,  recessive ,  stratification ,  radiology ,  survival ratio ,  *squamous cell carcinoma ,  *phase 3 study
Semi thesaurus term： 有害事象 ,  全生存率 ,  全生存期間 ,  エンドポイント ,  *転移性 ,  *セツキシマブ , 【Automatic Indexing@JST】

JST classification (2)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Treatment for mental disorders in general  (GR04010S)

Terms in the title (7)： 頭頚部 ,  再発 ,  転移性扁平上皮癌 ,  化学療法 ,  セツキシマブ ,  盲 ,  第3相試験